BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12680145)

  • 1. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.
    Takigawa N; Fujiwara K; Ueoka H; Kiura K; Tabata M; Hiraki A; Shibayama T; Segawa Y; Kamei H; Hiraki S; Tanimoto M; Harada M
    Anticancer Res; 2003; 23(1B):557-60. PubMed ID: 12680145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
    Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
    Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
    Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
    J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
    Ueoka H; Tanimoto M; Kiura K; Tabata M; Takigawa N; Segawa Y; Takata I; Eguchi K; Okimoto N; Harita S; Kamei H; Shibayama T; Watanabe Y; Hiraki S; Harada M
    Br J Cancer; 2001 Jul; 85(1):9-13. PubMed ID: 11437395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
    Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
    Lee JE; Park HS; Jung SS; Kim JO; Kim SY
    Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Kim EA; Yoon SM; Lee HG; Lee JS
    Med Oncol; 2005; 22(3):281-90. PubMed ID: 16110139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
    Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
    Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
    Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies of irinotecan alone and in combination with cisplatin.
    Fukuoka M; Masuda N
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S105-11. PubMed ID: 8070018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
    Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
    Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.
    Sohn JH; Moon YW; Lee CG; Kim GE; Chung KY; Chang J; Kim SK; Kim YS; Choi BW; Choi HJ; Kim JH
    Cancer; 2007 May; 109(9):1845-950. PubMed ID: 17366589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
    Klautke G; Fähndrich S; Semrau S; Büscher C; Virchow C; Fietkau R
    Lung Cancer; 2006 Aug; 53(2):183-8. PubMed ID: 16757061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
    Asano T; Namikawa O; Yamamoto A; Sano T; Mukai J; Kawaji K; Kobayashi M
    Nihon Kokyuki Gakkai Zasshi; 1998 Sep; 36(9):771-5. PubMed ID: 9866979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.